Detravenol, 1000 mg 30 pcs

The combination of hesperidin + diosmin has venotonic and angioprotective properties. It reduces venous distensibility and venous stasis, in the microcirculation – reduces capillary permeability and increases their resistance, improves indices of venous hemodynamics. It has an effect on the following venous plethysmographic parameters: venous capacity, venous extensibility, time of venous emptying.
The optimal effect is achieved when taking 1000 mg. The combination of hesperidin + diosmin increases venous tone by reducing the time of venous emptying. In patients with signs of marked microcirculatory disorders an increase in capillary resistance is noted.
The combination of hesperidin + diosmin is effective in treating chronic diseases of the veins of the lower limbs, as well as in the treatment of hemorrhoids.

Pharmacokinetics
The drug Detravenol is mainly excreted through the intestine. The average of about 14% of the administered dose is excreted by the kidneys.
Half-life period is 11 hours.
The drug is actively metabolized, which is proved by the presence of phenolic acids in the urine.

Indications

Treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).
Treatment of symptoms of venous-lymphatic insufficiency:
pain;
spasms of the lower extremities;
feeling of heaviness and fullness in the legs;
“tired” legs.
Treatment of manifestations of venous-lymphatic insufficiency:
swelling of the lower extremities;
trophic changes in the skin and subcutaneous tissue;
venous trophic ulcers.
Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

The combination of hesperidin + diosmin has venotonic and angioprotective properties. Reduces the distensibility of veins and venous stagnation, in microcirculation – reduces capillary permeability and increases their resistance, improves venous hemodynamics. It influences the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time.
The optimal effect is achieved when taking 1000 mg. The combination of hesperidin + diosmin increases venous tone by reducing the time of venous emptying. In patients with signs of severe microcirculation disorders, there is an increase in capillary resistance.
The combination of hesperidin + diosmin is effective in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Pharmacokinetics
The drug Detravenol is primarily excreted through the intestines. On average, about 14% of the dose taken is excreted by the kidneys.
The half-life is 11 hours.
The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Special instructions

Before you start taking Detravenol, it is recommended to consult your doctor.
In case of exacerbation of hemorrhoids, the use of Detravenol does not replace the specific treatment of other anal disorders.
The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy.
In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle; it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Hiking etc. in some cases, wearing special stockings helps improve blood circulation.
If there is no improvement or if the symptoms of the disease worsen, consult a doctor!

Do not exceed the maximum duration and recommended doses of the drug without consulting your doctor!

Impact on the ability to drive vehicles and machinery

The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

For 1 tablet:
active substance: purified micronized flavonoid fraction, including: diosmin (90%) – 450,000 mg; flavonoids in terms of hesperidin (10%) – 50,000 mg.
excipients (core): gelatin – 13,500 mg, sodium carboxymethyl starch -27,000 mg, magnesium stearate – 6,500 mg, microcrystalline cellulose – up to 650,000 mg.
shell composition: opadry II 85F240012 Pink – 20,000 mg: polyvinyl alcohol – 8,000 mg, macrogol-3350 – 4,876 mg, red iron oxide dye – 0.080 mg, yellow iron oxide dye – 0.044 mg, talc – 2,960 mg, titanium dioxide – 4,040 mg.

Contraindications

Hypersensitivity to the components of the drug;
Breastfeeding period (experience of use is limited).

Side Effects

The frequency of side effects is determined in accordance with the WHO classification of adverse drug reactions by frequency of occurrence; very often more than 1/10, often more than 1/100 and less than 1/10, infrequently more than 1/1000 and less than 1/100, rarely more than 1/10000 and less than 1/1000, very rarely less than 1/10000, including isolated cases; unknown frequency (it is impossible to determine the frequency of occurrence of an adverse reaction based on the available data).
From the central nervous system: rarely – headache, dizziness, general malaise.
From the gastrointestinal tract: often – diarrhea, dyspepsia, nausea, vomiting; infrequently – colitis; unspecified frequency – abdominal pain.
From the skin and subcutaneous fat: rarely – skin rash, itching, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema.
If you experience the side effects listed in the instructions, or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children.

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Ozon, Russia